Esperion to Report First Quarter 2023 Financial Results May 9, 2023
April 25 2023 - 8:00AM
Esperion (NASDAQ: ESPR), today announced it will report first
quarter 2023 financial results before the open of the U.S.
financial markets on Tuesday, May 9, 2023.
Following the release, company management will host a webcast at
8:00 a.m. ET to discuss financial results and business progress.
Please click here to pre-register to participate in the conference
call and obtain your dial in number and PIN.
Already registered? Access with your PIN here.
A live audio webcast can be accessed on the investor and media
section of the Esperion website at investor.esperion.com. Access to
the webcast replay will be available approximately two hours after
completion of the call and will be archived on the Company's
website for approximately 90 days.
ESPERION TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on Twitter at twitter.com/EsperionInc.
Contact:Corporate Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024